Abstract:BackgroundMETTL3 is known to be involved in all stages in the life cycle of RNA. It affects the tumor formation by the regulation the m6A modification in the mRNAs of critical oncogenes or tumor suppressors. In bladder cancer, METTL3 could promote the bladder cancer progression via AFF4/NF-κB/MYC signaling network by an m6A dependent manner. Recently, METTL3 was also found to affect the m6A modification in non-coding RNAs including miRNAs, lincRNAs and circRNAs. However, whether this mechanism is related to the proliferation of tumors induced by METTL3 is not reported yet.MethodsQuantitative real-time PCR, western blot and immunohistochemistry were used to detect the expression of METTL3 in bladder cancer. The survival analysis was adopted to explore the association between METTL3 expression and the prognosis of bladder cancer. Bladder cancer cells were stably transfected with lentivirus and cell proliferation and cell cycle, as well as tumorigenesis in nude mice were performed to assess the effect of METTL3 in bladder cancer. RNA immunoprecipitation (RIP), co-immunoprecipitations and RNA m6A dot blot assays were conducted to confirm that METTL3 interacted with the microprocessor protein DGCR8 and modulated the pri-miR221/222 process in an m6A-dependent manner. Luciferase reporter assay was employed to identify the direct binding sites of miR221/222 with PTEN. Colony formation assay and CCK8 assays were conducted to confirm the function of miR-221/222 in METTL3-induced cell growth in bladder cancer.ResultsWe confirmed the oncogenic role of METTL3 in bladder cancer by accelerating the maturation of pri-miR221/222, resulting in the reduction of PTEN, which ultimately leads to the proliferation of bladder cancer. Moreover, we found that METTL3 was significantly increased in bladder cancer and correlated with poor prognosis of bladder cancer patients.ConclusionsOur findings suggested that METTL3 may have an oncogenic role in bladder cancer through interacting with the microprocessor protein DGCR8 and positively modulating the pri-miR221/222 process in an m6A-dependent manner. To our knowledge, this is the first comprehensive study that METTL3 affected the tumor formation by the regulation the m6A modification in non-coding RNAs, which might provide fresh insights into bladder cancer therapy.

METTL3-mediated M6a Modification of KIF3C-mRNA Promotes Prostate Cancer Progression and is Negatively Regulated by Mir-320D.

METTL3 Promotes Prostate Cancer Progression by Regulating Mir-182 Maturation in M6a-Dependent Manner

METTL3 Regulates the Malignancy of Cervical Cancer Via Post-Transcriptional Regulation of RAB2B

METTL3-mediated M6a Modification of Pri-Mir-148a-3p Affects Prostate Cancer Progression by Regulating TXNIP

Methyltransferase-like 3 Promotes Cervical Cancer Metastasis by Enhancing Cathepsin L Mrna Stability in an N6-methyladenosine-dependent Manner

Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells

METTL3 facilitates prostate cancer progression via inducing HOXC6 m6A modification and stabilizing its expression through IGF2BP2-dependent mechanisms

Prognostic Value and Possible Mechanism of m6A Methyltransferase METTL3 in Prostate Cancer

The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation

Downregulation of N-6-methyladenosine Binding YTHDF2 Protein Mediated by Mir-493-3p Suppresses Prostate Cancer by Elevating N-6-methyladenosine Levels

METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

METTL3-Mediated m<SUP>6</SUP>A Modification of lncRNA MALAT1 Facilitates Prostate Cancer Growth by Activation of PI3K/AKT Signaling

MiR-573 Inhibits Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition.

The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target

SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells

The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.

Mir-137-3p Modulates the Progression of Prostate Cancer by Regulating the JNK3/EZH2 Axis.

Prognostic Values of METTL3 and Its Roles in Tumor Immune Microenvironment in Pan-Cancer

C-Met, CREB1 and EGFR Are Involved in Mir-493-5p Inhibition of EMT Via AKT/GSK-3β/Snail Signaling in Prostate Cancer

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma